Literature DB >> 29611723

Activation of tumor cell integrin αvβ3 by radiation and reversal of activation by chemically modified tetraiodothyroacetic acid (tetrac).

John T Leith1, Aleck Hercbergs2, Susan Kenney1, Shaker A Mousa3, Paul J Davis3,4.   

Abstract

PURPOSE: Integrin αvβ3 is an important structural and signaling protein of the plasma membrane of cancer cells and dividing blood vessel cells. The plastic extracellular domain of the protein binds to extracellular matrix proteins and plasma membrane proteins, changing cell-cell interactions and generating intracellular signals that influence cell behavior. αvβ3 also contains a receptor for thyroid hormone and derivatives, including tetraiodothyroacetic acid (tetrac).
MATERIALS AND METHODS: Human prostate cancer (PC3) cells were engrafted in the chicken chorioallantoic membrane model. The well-vascularized spheroidal xenografts were exposed to X-radiation in varying dosages (1-10 Gy) and in the presence and absence of an antibody that recognizes unliganded human β3 integrin monomer in the extended or open (activated) configuration.
RESULTS: Radiation significantly increased activated β3 within 1 h (P < .001), a radiation response not previously reported. Incubation of cells with unmodified tetrac or tetrac covalently linked to a nanoparticle (Nanotetrac, NDAT) did not change basal activation state of the integrin monomer, but prevented radiation-induced activation of β3.
CONCLUSIONS: Activation of the integrin in response to radiation is interpreted as a defensive response, perhaps leading to increased intercellular affinity and inhibition of cell division, a radioresistant state. Action of NDAT indicates that pharmacologic interventions in the radiation response of integrin β3 monomer and therefore of αvβ3 are feasible.

Entities:  

Keywords:  Integrin; integrin open configuration; radioresistance; tetrac; thyroid hormone

Mesh:

Substances:

Year:  2018        PMID: 29611723     DOI: 10.1080/07435800.2018.1456550

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  6 in total

Review 1.  Platelet ATP, Thyroid Hormone Receptor on Integrin αvβ3 and Cancer Metastasis.

Authors:  Paul J Davis; Shaker A Mousa; Geraldine P Schechter; Hung-Yun Lin
Journal:  Horm Cancer       Date:  2019-12-14       Impact factor: 3.869

Review 2.  Actions of L-thyroxine (T4) and Tetraiodothyroacetic Acid (Tetrac) on Gene Expression in Thyroid Cancer Cells.

Authors:  Paul J Davis; Hung-Yun Lin; Aleck Hercbergs; Shaker A Mousa
Journal:  Genes (Basel)       Date:  2020-07-07       Impact factor: 4.096

3.  In Vivo Clearance of Apoptotic Debris From Tumor Xenografts Exposed to Chemically Modified Tetrac: Is There a Role for Thyroid Hormone Analogues in Efferocytosis?

Authors:  Kavitha Godugu; Shaker A Mousa; Gennadi V Glinsky; Hung-Yun Lin; Paul J Davis
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-04       Impact factor: 5.555

Review 4.  Actions of Thyroid Hormones on Thyroid Cancers.

Authors:  Shaker A Mousa; Aleck Hercbergs; Hung-Yun Lin; Kelly A Keating; Paul J Davis
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-21       Impact factor: 5.555

5.  Collective cancer invasion forms an integrin-dependent radioresistant niche.

Authors:  Anna Haeger; Stephanie Alexander; Manon Vullings; Fabian M P Kaiser; Cornelia Veelken; Uta Flucke; Gudrun E Koehl; Markus Hirschberg; Michael Flentje; Robert M Hoffman; Edward K Geissler; Stephan Kissler; Peter Friedl
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

6.  Cancer-Associated Thrombosis: Risk Factors, Molecular Mechanisms, Future Management.

Authors:  Marwa S Hamza; Shaker A Mousa
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.